Stock analysts at Cantor Fitzgerald began coverage on shares of TrovaGene (NASDAQ: TROV) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $10.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 45.56% from the stock’s previous close.
The analysts wrote, “We are initiating coverage of Trovagene, Inc. with a BUY rating and $10 PT. TROV is a development-stage molecular diagnostic company with about 20 employees, but has a unique technology platform that is capable of analyzing systemic cell-free DNA and RNA isolated from urine. TROV’s technology has the potential to provide truly non-invasive diagnostic applications across various disease areas and health conditions, including cancer, infectious diseases, transplant medicine and prenatal diagnostics.”
TrovaGene (NASDAQ: TROV) opened at 6.87 on Monday. TrovaGene has a 1-year low of $2.09 and a 1-year high of $8.96. The stock’s 50-day moving average is currently $6.64. The company’s market cap is $107.3 million.
TrovaGene (NASDAQ: TROV) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.02. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.03 million. Analysts expect that TrovaGene will post $-0.44 EPS for the current fiscal year.
Separately, analysts at Thomson Reuters/Verus initiated coverage on shares of TrovaGene in a research note to investors on Tuesday, April 30th. They set a “hold” rating on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.